MedPeerInc Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yo Iwami

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	18.9yrs
Participación del CEO	31.1%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Yo Iwami (49 yo)

18.9yrs

Permanencia

Dr. Yo Iwami, M.D, Ph D., serves as the President and Representative Director of MedPeer,Inc since June 2005 and serves as its CEO. Dr. Iwami has been an Outside Director of Sogo Rinsho Holdings Co., Ltd....

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yo Iwami	President	18.9yrs	sin datos	31.14% ¥ 4.6b
Naoki Goto	Executive VP & Director	less than a year	sin datos	0.0046% ¥ 675.4k
Makoto Haruta	Management Advisor	no data	sin datos	sin datos
Takashi Hayama	External Auditor	11.4yrs	sin datos	0.38% ¥ 56.1m
Hiroyasu Sato	External Auditor	11.4yrs	sin datos	sin datos
Masatoshi Kawana	Independent Outside Director	4.4yrs	sin datos	sin datos
Yoshihiko Tembo	Director	3.4yrs	sin datos	0.15% ¥ 22.1m
Toshio Hirabayashi	Director	3.4yrs	sin datos	0.28% ¥ 41.7m
Mayuko Seto	Independent Outside Director	1.4yrs	sin datos	sin datos
Masayuki Shimura	Independent Outside Director	1.4yrs	sin datos	0.0014% ¥ 202.6k
Shunichi Sueyoshi	Full Time Auditor	6.4yrs	sin datos	sin datos

3.9yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 6095 se considera experimentada (3.8 años de antigüedad promedio).

MedPeerInc Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

No independent directors

MedPeer,Inc., Annual General Meeting, Dec 17, 2020

Recent updates

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥60.05 (vs JP¥34.99 in FY 2020)

Price target decreased to JP¥5,793

Third quarter 2021 earnings released: EPS JP¥8.03 (vs JP¥6.92 in 3Q 2020)

Price target decreased to JP¥6,293

Second quarter 2021 earnings released: EPS JP¥15.46 (vs JP¥9.17 in 2Q 2020)

MedPeer,Inc. to Report Q2, 2021 Results on May 13, 2021

New 90-day low: JP¥6,080

Analysts update estimates

First quarter 2021 earnings released: EPS JP¥20.34 (vs JP¥7.58 in 1Q 2020)

MedPeer,Inc. to Report Q1, 2021 Results on Feb 15, 2021

New 90-day high: JP¥7,270

Price target raised to JP¥6,043

New 90-day high: JP¥6,980

MedPeer,Inc., Annual General Meeting, Dec 17, 2020